was noted with low doses of prednisone, however, in contrast with the dramatic improvement obtained in the original papers. On the other hand, synovial biopsy in our case did not show malignant infiltration. Thus it is reasonable to suggest that the rheumatic manifestations belong to a paraneoplastic syndrome, as has been previously reported with other neoplasms.

To our knowledge this is the first description of peripheral synovitis and pitting oedema as an initial manifestation of non-Hodgkin’s lymphoma. We would like to emphasise the need to consider the possibility of an underlying malignancy in a patient with these clinical characteristics who is unresponsive to the usual medical treatment.

M R ROLDAN  
J M MARTINEZ  
Department of Rheumatology  
"Reina Sofia" Hospital  
Cordoba  
Spain

J ROMAN  
A TORRES  
Department of Hematology  
"Reina Sofia" Hospital  
Cordoba  
Spain

Malignant lymphoma and arthritis: a case report

Correspondence to: M Rosa Roldan Molina, c/Sánchez de Feria 3, 1st 3, 41003 Cordoba, Spain.


Arthritis and carcinoma

SIR: We read with interest the paper by Chakravarty and Webley describing two cases of asymptomatic renal cell carcinoma causing an acute monarthrosis, previously unreported. They suggested that this occurrence is both rare and underreported. In our experience this is not necessarily the case. We have recently seen two patients whose cases illustrate some interesting similarities.

Patient No 1, a 63 year old man presented to our hospital with a five week history of a painful, swollen knee joint and was unable to bear weight. Clinical examination confirmed an acute monarthrosis of the knee joint, with a tense effusion, warmth, and tenderness. He had a history of diabetes and was treated for a large cell solid temporo-orbital tumour by radiotherapy because the lesion was considered inoperable. The knee joint effusion was aspirated to rule out sepsis. Bacteriology was negative, no crystals were found, but adenocarcinoma cells were seen in abundance. He made an excellent functional recovery after palliative irradiation to the knee.

Patient No 2, a 63 year old woman, was referred to the radiotherapy department of the same hospital with metastatic disease for which no primary tumour had been located despite extensive investigation. She had initially presented with a painful knee of one-year’s duration. Clinical examination showed an acute monarthrosis with a moderate effusion. Isotope bone scan disclosed a hot spot in the upper tibia. She had a synovial biopsy and cytological examination of the synovial fluid. The synovial biopsy sample showed evidence of infiltration with adenocarcinomatous cells as did the synovial fluid.

While we agree with the authors that in cases where there is doubt about the cause of a joint effusion, early examination of synovial fluid is important, and may prevent the need for an open or closed bone biopsy, we are of the opinion that the occurrence of malignant joint effusions is not rare but likely to be underreported.

Ciaran Dunne  
Tim Illidge  
Poole Hospital  
Longfleet Road  
Poole

Dorset BH15 2JB  
United Kingdom

Angiotensin converting enzyme in rheumatoid arthritis

Sir: Being interested in vascular endothelial cell transdifferentiation, I read with interest the instructive articles by Veale et al2 and Goto et al3 about the angiotensin converting enzyme production in rheumatoid arthritis. Although there is no doubt that vascular endothelial cells participate in this process, the role of macrophages remains questionable because the antibodies used for their identification (antigen CD14) are not macrophage specific and cross react with vascular endothelial cells.4 Moreover, undifferentiated vascular endothelial cells can transdifferentiate into macrophage-like cells and migrate into the extravascular space.5 It may be useful to re-evaluate the role of macrophages in rheumatoid arthritis in the light of the new knowledge about the transdifferentiation of vascular endothelium.6 For example, the mesenchymal transformation cells responsible for joint destruction differentiate into fibroblasts in due course6 and are not, therefore, inflammatory cells. McCachren considers, however, any collagenase producing cells immunoreactive with Leu-M3 or HAM56 to be macrophages.8 Again, these antibodies are not macrophage specific and cross react with vascular endothelial cells.9 Histopathological transformation cells found in undifferentiated vascular endothelial cells by their character and aggressiveness.7 The facts that antiangiogenesis suppresses arthritis10 and that angiotensin II is an angiogenic factor11 are in excellent keeping with that proposition.

Jiri T Beranek  
Department of Medicine  
UMC-School of Medicine  
Columbia, Missouri  
USA


Endothelium damage and von Willebrand factor antigen

Sir: We read with great interest the recent paper by Blann et al on damage to the endothelium in Sjögren’s syndrome.1 The authors examined the relation of the autoantibodies SSA and SSB to endothelium damage using serum levels of von Willebrand factor antigen (vWF:Ag) as an index of damage to the endothelium.

Damage of the endothelium may be present in Sjögren’s syndrome, but there is no real evidence whether such damage results in high or low levels of VWF:Ag. The extent of the production of vWF:Ag in megakaryocytes in Sjögren’s syndrome and other diseases is unknown; mainly because the contribution of the factor do not follow changes in the numbers of thrombocytes in peripheral blood and so this production site is no longer a part of the scenario. Further, in our opinion, endothelium damage cannot explain why increased concentrations of vWF:Ag are present in such varied diseases as proliferative glomerulonephritis, diabetes mellitus, systemic sclerosis, Sjögren’s syndrome, and arteritis temporals, as endothelial damage in these diseases is not a common denominator.

We have recently studied the immunohistochemistry in arteritis temporals, in which
Arthritis and carcinoma.

C Dunne and T Illidge

*Ann Rheum Dis* 1993 52: 86
doi: 10.1136/ard.52.1.86-a

Updated information and services can be found at:
http://ard.bmj.com/content/52/1/86.1.citation

*These include:*

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/